Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.

ABSTRACT: Cognitive impairment is common in Parkinson's disease (PD), but often not improved by dopaminergic treatment. New treatment strategies targeting other neurotransmitter deficits are therefore of growing interest. Imaging the brain at rest ('task-free') provides the opportunity to examine the impact of a candidate drug on many of the brain networks that underpin cognition, while minimizing task-related performance confounds. We test this approach using atomoxetine, a selective noradrenaline reuptake inhibitor that modulates the prefrontal cortical activity and can facilitate some executive functions and response inhibition. Thirty-three patients with idiopathic PD underwent task-free fMRI. Patients were scanned twice in a double-blind, placebo-controlled crossover design, following either pl

SUBMITTER: Borchert RJ 

PROVIDER: S-EPMC4856878 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature